Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on December 11, 2006

Circulation. 2006
Published online before print December 11, 2006, doi: 10.1161/CIRCULATIONAHA.106.658088
A more recent version of this article appeared on December 19, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
114/25/2815    most recent
CIRCULATIONAHA.106.658088v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, M.-J.
Right arrow Articles by Park, S.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, M.-J.
Right arrow Articles by Park, S.-J.
Related Collections
Right arrow Echocardiography

Submitted on August 14, 2006
Revised on September 28, 2006
Accepted on October 19, 2006

Long-Term Outcomes of Significant Mitral Regurgitation After Percutaneous Mitral Valvuloplasty

Mi-Jeong Kim MD, Jae-Kwan Song MD*, Jong-Min Song MD, Duk-Hyun Kang MD, Young-Hak Kim MD, Cheol Whan Lee MD, Myeong-Ki Hong MD, Jae-Joong Kim MD, Seong-Wook Park MD, and Seung-Jung Park MD

From the Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

* To whom correspondence should be addressed. E-mail: jksong{at}amc.seoul.kr.

Background--Mild commissural mitral regurgitation (MR) is associated with significantly higher restenosis-free survival after percutaneous mitral valvuloplasty (PMV), which suggests that different mechanisms of significant MR after PMV may have different clinical courses. We therefore analyzed long-term prognostic factors of significant MR after PMV.

Methods and Results--Echocardiographic and clinical follow-up data on 380 patients were analyzed (286 women, mean age 44±11 years) who underwent PMV with the Inoue balloon technique between 1995 and 2000. Significant MR developed in 47 patients (12.4%). The survival rate at 8 years was 96±3% and 98±10% in patients with and without significant MR, respectively (P=0.084). The most frequent mechanism was commissural MR, or MR that originated at the site of successful commissurotomy, which occurred in 27 of 47 patients (57%), whereas noncommissural MR occurred in 20 (43%) patients, 12 (26%) with subvalvular damage resulting in chordae rupture and flail motion and 8 (17%) with leaflet laceration. The 8-year event-free survival rate was significantly lower in patients with significant MR than in those without (47±8% versus 83±3%, P<0.001) and was significantly higher in patients with commissural versus noncommissural MR (63±11% versus 29±11%, P<0.001). Of the 47 patients with significant MR, who were followed up for 74±29 months, 19 patients (40%) underwent mitral valve replacement, and 28 patients (60%) received medical treatment only. Patients with commissural MR had a significantly lower rate of mitral valve replacement than patients with noncommissural MR (15% versus 70%, P<0.001). Multivariate analysis showed that atrial fibrillation (odds ratio, 7.4; 95% CI, 1.1 to 56.4; P=0.038), mean mitral gradient immediately after PMV (odds ratio, 1.5; 95% CI, 1.1 to 2.0; P=0.009), and the mechanism of MR (odds ratio, 16.7; 95% CI, 2.3 to 122.2; P=0.005) were independent factors associated with mitral valve replacement.

Conclusions--Clinical outcome of patients with significant MR after PMV varied according to MR mechanism and the adequacy of hemodynamic improvement, which is easily assessed by echocardiography immediately after PMV.


Key words: echocardiography • valvuloplasty • regurgitation • mitral valve stenosis




This article has been cited by other articles:


Home page
Eur Heart JHome page
J.-K. Song, J.-M. Song, D.-H. Kang, S.-C. Yun, D. W. Park, S. W. Lee, Y.-H. Kim, C. W. Lee, M.-K. Hong, J.-J. Kim, et al.
Restenosis and adverse clinical events after successful percutaneous mitral valvuloplasty: immediate post-procedural mitral valve area as an important prognosticator
Eur. Heart J., May 2, 2009; 30(10): 1254 - 1262.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Nobuyoshi, T. Arita, S.-i. Shirai, N. Hamasaki, H. Yokoi, M. Iwabuchi, H. Yasumoto, and H. Nosaka
Percutaneous Balloon Mitral Valvuloplasty: A Review
Circulation, March 3, 2009; 119(8): e211 - e219.
[Full Text] [PDF]


Home page
Obstet MedHome page
S. Tsiaras and A. Poppas
Mitral valve disease in pregnancy: outcomes and management
Obstet Med, March 1, 2009; 2(1): 6 - 10.
[Abstract] [Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
A. Vahanian, B. Iung, L. Piérard, R. Dion, and J. Pepper
CHAPTER 21 Valvular Heart Disease
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. H. Rahimtoola
The Year in Valvular Heart Disease.
J. Am. Coll. Cardiol., February 19, 2008; 51(7): 760 - 770.
[Full Text] [PDF]